BR112017004284A2 - métodos para o tratamento e prevenção de doenças vasculares - Google Patents

métodos para o tratamento e prevenção de doenças vasculares

Info

Publication number
BR112017004284A2
BR112017004284A2 BR112017004284A BR112017004284A BR112017004284A2 BR 112017004284 A2 BR112017004284 A2 BR 112017004284A2 BR 112017004284 A BR112017004284 A BR 112017004284A BR 112017004284 A BR112017004284 A BR 112017004284A BR 112017004284 A2 BR112017004284 A2 BR 112017004284A2
Authority
BR
Brazil
Prior art keywords
vascular diseases
prevention
treatment
methods
relates
Prior art date
Application number
BR112017004284A
Other languages
English (en)
Inventor
Alexandra Figtree Gemma
Original Assignee
Alexandra Figtree Gemma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014903547A external-priority patent/AU2014903547A0/en
Application filed by Alexandra Figtree Gemma filed Critical Alexandra Figtree Gemma
Publication of BR112017004284A2 publication Critical patent/BR112017004284A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se aos métodos de tratamento e/ou prevenção de doenças vasculares. a presente invenção também se refere a um dispositivo médico para implantação em um paciente que passa por terapia vascular, o dispositivo compreendendo uma quantidade terapêutica de fxyd1 ou um derivado desta capaz de interação com a sintase de óxido nítrico endotelial. a presente invenção também se refere ao uso de fxyd1 e seus derivados e variantes capazes de interação com a sintase de óxido nítrico endotelial para o tratamento ou prevenção de doenças vasculares.
BR112017004284A 2014-09-05 2015-09-07 métodos para o tratamento e prevenção de doenças vasculares BR112017004284A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2014903547A AU2014903547A0 (en) 2014-09-05 Method for treatment and prevention of vascular disease
PCT/AU2015/000548 WO2016033643A1 (en) 2014-09-05 2015-09-07 Methods for treatment and prevention of vascular disease

Publications (1)

Publication Number Publication Date
BR112017004284A2 true BR112017004284A2 (pt) 2017-12-05

Family

ID=55438918

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017004284A BR112017004284A2 (pt) 2014-09-05 2015-09-07 métodos para o tratamento e prevenção de doenças vasculares

Country Status (7)

Country Link
US (1) US20180185444A1 (pt)
EP (1) EP3188744A4 (pt)
JP (1) JP2017532370A (pt)
CN (1) CN107106646A (pt)
AU (1) AU2015311606A1 (pt)
BR (1) BR112017004284A2 (pt)
WO (1) WO2016033643A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919655A (en) * 1996-10-25 1999-07-06 Incyte Pharmaceuticals, Inc. Human phospholemman homolog
CA2777250A1 (en) * 2009-10-15 2011-04-21 Helge H. Rasmussen Na-k pump modulation
JP5725490B2 (ja) * 2010-04-14 2015-05-27 国立大学法人鳥取大学 レチノイン酸受容体リガンドの抗腫瘍作用、発癌抑制作用を含めた種々の作用を決定する遺伝子の同定
US20190300965A1 (en) * 2016-07-06 2019-10-03 Youhealth Biotech, Limited Liver cancer methylation markers and uses thereof
JP2020521452A (ja) * 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容

Also Published As

Publication number Publication date
EP3188744A1 (en) 2017-07-12
US20180185444A1 (en) 2018-07-05
EP3188744A4 (en) 2018-03-28
CN107106646A (zh) 2017-08-29
JP2017532370A (ja) 2017-11-02
WO2016033643A1 (en) 2016-03-10
AU2015311606A1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112017025166A2 (pt) métodos de condicionar pacientes para terapia de células t
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
BR112017016759A2 (pt) recipiente de plástico pré-carregado, kit, uso do recipiente de plástico pré-carregado, método para o tratamento de uma doença ou condição, método para o tratamento cosmético da pele
MX2021000289A (es) Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.
BR112019008384A2 (pt) composição farmacêutica, processos para tratamento e seus usos
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112019005351A2 (pt) terapia combinada com agonistas de cnp de liberação controlada
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
BR112016026545A8 (pt) eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama
BR112017015576A2 (pt) método para o tratamento de câncer, artigo, método para monitorizar, método para a otimização da eficácia terapêutica, método para a identificação de um biomarcador, utilização, combinação terapêutica, combinação para a utilização e produto
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase
BR112017013674A2 (pt) métodos e composições para tratamento de doenças cerebrais.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
BR112018067554A2 (pt) formulações de testosterona e métodos de tratamento com as mesmas
PH12017500392A1 (en) Medical treatments based on anamorelin

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired